Crisaborole is a non-steroidal topical medication used primarily for the treatment of mild to moderate atopic dermatitis (eczema). It works by inhibiting the enzyme phosphodiesterase-4 (PDE-4), which helps reduce inflammation in the skin. Crisaborole was developed by the pharmaceutical company Anacor Pharmaceuticals, which focused on boron-based therapeutics, and later gained wider recognition after being acquired by Pfizer in 2016. Following successful clinical trials demonstrating its safety and efficacy, the drug was approved by the U.S. Food and Drug Administration in 2016 under the brand name Eucrisa, marking an important advancement as one of the first topical PDE-4 inhibitors for eczema treatment. Its introduction provided an alternative to corticosteroids and calcineurin inhibitors, particularly for patients seeking a steroid-free option with a favorable safety profile.
